文章核心观点 - 公司的主要管线候选药物是certepetide,正在开发用于治疗多种实体瘤 [1][2][4] - 最新的临床前研究显示,certepetide联合标准化疗和免疫治疗可以改善小鼠肝内胆管癌的生存期 [3][4][5] - 公司计划在BOLSTER II期临床试验中增加一个评估certepetide联合标准化疗和免疫治疗治疗肝内胆管癌的研究组 [6] - 公司股价今年迄今上涨33.7%,超过行业下跌2.7% [7] - certepetide正在多项早中期临床试验中评估作为联合疗法治疗多种癌症适应症,包括转移性胰腺导管腺癌 [8] - FDA已经授予certepetide治疗骨肉瘤、胰腺癌和胶质母细胞瘤的孤儿药资格,并给予胰腺癌的快速通道资格 [9][10] - 未来几个月内,公司有望从多项certepetide的临床试验中获得积极数据,这将大幅提升公司的增长前景 [12][13]

文章核心观点 - 公司宣布其BOLSTER临床试验的首次适应症-一线胆管癌的入组提前完成,预计将于2025年中获得试验的主要结果 [2][3][4] - 公司还新增了二线胆管癌适应症的试验,预计将于2024年第四季度开始入组 [3] - 胆管癌是一种罕见但严重的癌症,5年生存率不到5%,迫切需要新的有效治疗方法 [5] - 公司的主要产品候选物certepetide旨在激活一种新的摄取通路,使共同给药或连接的抗癌药物更有效地渗透和积累在肿瘤中 [6][8] 公司概况 - 公司是一家临床阶段制药公司,专注于开发创新疗法治疗晚期实体瘤和其他严重疾病 [7][8] - 公司预计未来两年内将宣布多个里程碑事件,并相信目前的资本可为其运营提供资金支持,直至2026年初 [8] 行业概况 - 胆管癌是一种发生在胆管中的癌症,是一种罕见但严重的癌症 [5] - 美国每年约有8,000人被诊断患有胆管癌,但实际数字可能更高,因为诊断存在挑战 [5] - 胆管癌的5年生存率不到5%,迫切需要新的有效治疗方法 [5]

Complete enrollment achieved nearly six months ahead of plan Top-line data now anticipated mid-2025 Addition of second-line cholangiocarcinoma arm to BOLSTER trial BASKING RIDGE, N.J., July 16, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, announced today the early completion of enrollment in its Phase 2a BOLSTER trial ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

文章核心观点 - 该公司是一家专注于提供金融新闻和在线广播的公司,拥有遍布全球主要金融中心的新闻团队[1][2][3] - 公司专注于中小市值公司的报道,同时也关注蓝筹股、大宗商品和新兴技术等投资故事[3][4] - 公司采用前瞻性的技术手段,包括使用自动化和软件工具,但所有内容仍由人工编辑和撰写[5][6][7] 公司概况 - 公司拥有遍布全球主要金融中心的新闻团队,包括伦敦、纽约、多伦多、温哥华、悉尼和珀斯等地[2] - 公司专注于报道中小市值公司,同时也关注蓝筹股、大宗商品和新兴技术等投资故事,为投资者提供及时、有价值的内容[3][4] - 公司采用前瞻性的技术手段,包括使用自动化和软件工具,但所有内容仍由人工编辑和撰写,以确保内容质量[5][6][7]

Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo joined Proactive to discuss a recent milestone for the company: the completion of patient enrollment in the pancreatic cancer cohort of its Phase 1b/2a CENDIFOX trial. The trial is evaluating the safety and efficacy of certepetide (formerly LSTA1) in combination with FOLFIRINOX-based therapies for pancreatic, colon, and appendiceal cancers. Mazzo explained to Proactive that this trial combines the company’s lead program, certepetide with a standard of ca ...

文章核心观点 - 公司宣布完成胰腺癌队列的患者入组,这是CENDIFOX试验的一个重要里程碑 [1][2] - CENDIFOX试验旨在评估certepetide与FOLFIRINOX方案联合用药在胰腺癌、结肠癌和阑尾癌中的安全性和疗效 [2] - 该试验由堪萨斯大学癌症中心的Anup Kasi博士主导,Lisata公司提供certepetide药物 [2][3] - certepetide是一种新型药物,可以促进联合用药或共价连接的抗肿瘤药物更有效地渗透和积累在肿瘤中 [4][5] - Lisata公司正在探索certepetide在多种实体瘤治疗中的潜力,该药物已获得多项快速通道和孤儿药认定 [5] 公司概况 - Lisata Therapeutics是一家临床阶段制药公司,专注于开发创新的实体瘤和其他重大疾病治疗方案 [6][7] - 公司预计未来两年内将宣布多个里程碑事件,并相信目前的资金可以支持到2026年初的预期临床试验数据节点 [7] 风险提示 - 临床试验结果可能与单个病例观察结果不同,需要更多病例数据和长期随访来确认疗效 [8] - 公司产品候选药物在早期研究和临床试验中表现良好,但最终可能无法在大规模或后期临床试验中证实安全性和有效性 [8] - 公司未来的发展受到多方面因素的影响,包括监管审批、融资能力、知识产权保护等 [8]

Phase 1b/2a open-label trial in the U.S. of certepetide in combination with neoadjuvant FOLFIRINOX based therapies in pancreatic, colon and appendiceal cancers BASKING RIDGE, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, announced today the successful completion of patient enrollment for the pancreatic c ...

About this content About William Farrington William kickstarted his career as a researcher and reporter for a global legal publication, covering everything from public law to M&A. Before moving to Proactive Investors, he worked as a reporter for a major fintech company with a focus on cryptocurrency and blockchain technology. Harking from Queensland, Australia, William obtained first-class honours in journalism and media from Birkbeck University before going on to complete an MA in creative and critical wri ...

Waiver confirms that paediatric studies of certepetide in pancreatic cancer are not needed Significant clinical trial burden and costs avoided due to waiver BASKING RIDGE, N.J., May 20, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that it has reached agreement with the European Medicines Agency (the "EM ...